Loading…
← CockpitCompetitor Analysis › BCAX Bicara Therapeutics Inc.Open in the cockpit ↗

Bicara Therapeutics Inc.BCAXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech developing a bifunctional EGFR/TGF-beta-trap antibody (ficerafusp alfa) for head-and-neck and other solid tumors.

Momentum laggard 3
Mkt cap
$623M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$23.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$9.38
1D-2.3%
1W-10.9%
1M-48.9%
3M-61.5%
6M-54.1%
YTD-44.3%
1Y-37.7%
ATR %11.7%
Beta1.29
52w lowhigh69.7% off high

What Bicara Therapeutics does

Biotech developing a bifunctional EGFR/TGF-beta-trap antibody (ficerafusp alfa) for head-and-neck and other solid tumors.

Has no product revenue and funds trials by selling shares, so each data readout and financing round shapes what it can afford to run. Ficerafusp alfa attacks a tumour in two ways, blocking a growth receptor (EGFR) and neutralising a signal (TGF-beta) that helps tumours hide from the immune system, and it is tested alongside a checkpoint-inhibitor drug.

Products and services

  • Ficerafusp alfa (head & neck cancer)
  • Pipeline bifunctional antibodies

Where it sits in the supply chain

  • Biopharma R&D
  • Bifunctional antibody engineering
  • Solid-tumor clinical development

What could go right

  • Positive pivotal trial data
  • Partnership/licensing deal with big pharma

What could go wrong

  • Binary late-stage trial risk
  • Single-lead-asset concentration

Moat: none (IP / patents). Pre-commercial; differentiation rests on unproven combined EGFR/TGF-beta mechanism data.

Headquarters: Boston, Massachusetts, US · Founded: 2021 · Employees: 103

Named competitors

Bicara Therapeutics at a glance

Size Bicara Therapeutics (BCAX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $623M, the 2530th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.38 on 18 Nov 2026.

Performance Over six months the shares fell 54.1%, against -19.0% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 20 in its peer set.

Short interest Short interest is 14.9% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026Peer median 81BCAX 45
Six months, rebased to 100: Bicara Therapeutics against the median of its 20 peers (local-currency closes).

Bicara Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$191,000-$105,000-$56,000-$19,000-$10,000
EBITDA-$237M-$155M-$82.3M-$39.9M-$37.6M
Net income-$220M-$138M-$68.0M-$52.0M-$37.8M
Free cash flow-$163M-$107M-$74.8M-$46.2M-$32.3M
Capital expenditure$1.02M$280,000$71,000$586,000$192,000
Total debt$880,000$1.71M$738,000$657,000$0

Quarterly statements and history in the cockpit →

Bicara Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%301211OLMAABUS4105300878ORCHPHARMA3001940029406035670027931857504123000566DBVINNOVACAP600976BCAX6-month return →1-month return →
Up and to the right = strong over both horizons. Bicara Therapeutics is the large dot.

Bicara Therapeutics competitors and peer comparison

Head to head with its named competitors (BCAX vs MRK vs BMY vs 1801.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Bicara Therapeutics BCAX$623M-54%n/an/an/an/a
Merck & MRK$340B+23%+5%18%5.7×8.3%
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%

How Bicara Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bicara Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureBCAXPeer medianRank in peer set
1-month return-48.9%-10.2%lowest of 20
6-month return-54.1%-19.0%lowest of 20
Distance from 52-week high-69.7%-38.0%2nd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%

Questions

Who are Bicara Therapeutics's main competitors?
Named competitors: Merck (MRK), Bristol Myers Squibb (BMY), Innovent Biologics (1801.HK). The cockpit's measured peer set (industry) also includes Hubei Biocause Heilen Pharmaceutical (301211.SZ), Olema Pharmaceuticals (OLMA), Arbutus Biopharma (ABUS), TTY Biopharm (4105.TWO), Zhejiang Wecome Pharmaceutical (300878.SZ), Orchid Pharma (ORCHPHARMA.NS).
How has Bicara Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -54.1% against -19.0% for the median peer; over one year -37.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.